Genentech Inc. said it has reached agreement...

Genentech Inc. said it has reached agreement with Mitsubishi Kasei to develop and market in the United States pharmaceutical products made by the Japanese company. Genentech Chief Executive Robert A. Swanson said the first of these products will be argatroban, which acts as a clot-inhibiting agent in blood. Swanson said clinical trials will be conducted to determine if argatroban could be used in conjunction with Genentech’s Activase clot-dissolving drug. The South San Francisco-based firm also confirmed a previous forecast that 1988 product sales increased by more than 80% from the previous year.